10543 studies found for:    NCI
Show Display Options
Rank Status Study
1 Active, not recruiting Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Conditions: Cognitive Side Effects of Cancer Therapy;   Fatigue;   Neurotoxicity Syndrome;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-Related Toxicity;   Waldenstrom Macroglobulinemia
Interventions: Drug: Temsirolimus;   Biological: Rituximab;   Drug: Bortezomib;   Drug: Dexamethasone;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
2 Completed Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis
3 Active, not recruiting Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
Conditions: HER2-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: epirubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
4 Recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Conditions: Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: Lenalidomide;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Other: Laboratory Biomarker Analysis
5 Completed Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: rituximab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: pharmacological study
6 Active, not recruiting Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Conditions: Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Sunitinib Malate;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
7 Completed Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Drug: tamoxifen citrate
8 Completed Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Carcinoma;   Stage IIIA Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Drug: Temsirolimus;   Other: Laboratory Biomarker Analysis
9 Completed 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: tanespimycin;   Other: laboratory biomarker analysis
10 Active, not recruiting Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
Conditions: Colon Cancer;   Crohn Disease-associated Dysplasia;   Rectal Cancer;   Ulcerative Colitis-associated Low-grade Dysplasia
Interventions: Drug: inositol;   Other: placebo;   Other: laboratory biomarker analysis
11 Terminated Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery
Conditions: Mucinous Adenocarcinoma of the Rectum;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIA Rectal Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Rectal Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: capecitabine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: irinotecan hydrochloride;   Drug: oxaliplatin;   Radiation: external beam radiation therapy;   Other: laboratory biomarker analysis
12 Recruiting Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Condition: Malignant Neoplasm
Intervention: Other: Laboratory Biomarker Analysis
13 Completed Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Biological: oblimersen sodium;   Drug: imatinib mesylate;   Other: laboratory biomarker analysis
14 Withdrawn Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
Conditions: AIDS-related Kaposi Sarcoma;   Classic Kaposi Sarcoma
Interventions: Drug: sunitinib malate;   Procedure: laboratory biomarker analysis;   Procedure: pharmacological study
15 Not yet recruiting Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
Conditions: Adult Brain Glioblastoma;   Recurrent Adult Brain Neoplasm
Interventions: Drug: Methoxyamine;   Drug: Temozolomide;   Other: Laboratory Biomarker Analysis
16 Active, not recruiting Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: placebo;   Drug: vismodegib;   Other: laboratory biomarker analysis
17 Active, not recruiting Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
Conditions: Ovarian Clear Cell Adenocarcinoma;   Recurrent Ovarian Carcinoma
Interventions: Drug: Sunitinib Malate;   Other: Laboratory Biomarker Analysis
18 Completed O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: O6-benzylguanine;   Drug: polifeprosan 20 with carmustine implant;   Procedure: conventional surgery
19 Active, not recruiting Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
20 Completed AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Intraocular Melanoma;   Iris Melanoma;   Lentigo Maligna Malignant Melanoma;   Recurrent Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years